NeuVasQ

Executive Summary

NeuVasQ Biotechnologies is a Belgian preclinical-stage biotech developing first-in-class Wnt surrogate antibodies targeting Gpr124 and Reck receptors to restore blood-retina and blood-brain barrier integrity. This novel approach addresses vascular retinopathies and severe neurological disorders with high unmet need. Founded in 2018 and based in Leuven, the company leverages proprietary biology to modulate Wnt signaling, a pathway critical for vascular health. While still in early development and lacking disclosed funding or pipeline milestones, NeuVasQ's platform has potential for transformative impact if preclinical validation succeeds. The company's progress will hinge on advancing lead candidates toward IND-enabling studies and securing partnerships or financing.

Upcoming Catalysts (preview)

• Q4 2026Presentation of preclinical in vivo efficacy data at a major conference60% success
• Q2 2027Series A or B funding round50% success
• Q4 2027First IND filing for lead candidate in a neurological indication30% success